Recently, targeted therapies including PD1 (programmed cell death 1) antibodies, such as pembrolizumab and nivolumab, have been approved by the Food and Drug Administration for use in advanced GC patients [3]. This evidence concerns the gene PDCD1 and gastric cancer.